Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study

Celcuity Inc. presented updated results from the PIK3CA mutation cohort of its Phase 3 VIKTORIA-1 clinical trial at the ESMO Congress 2026. The trial evaluates gedatolisib, the company's lead therapeutic candidate, in patients with HR+/HER2- advanced breast cancer, showcasing new clinical data on its efficacy. This presentation underscores Celcuity's ongoing progress in its late-stage clinical development for targeted oncology therapies.